China's CRISPR-edited genes trial to treat lung cancer in humans successful
Ocnologists From China Were The First To Place CRISPR-modified Cells Into A Lung Cancer Patient, According To Nature. The Journal Says That Second Injection Of Cas9-edited Cells Is Sure And Nine More People Will Be Treated In Future As The Safety Trial First Round Of Treatment Went Well.
Ocnologists from China were the first to place CRISPR-modified cells into a lung cancer patient, according to Nature. The journal says that second injection of Cas9-edited cells is sure and nine more people will be treated in future as the safety trial first round of treatment went well. Further, the patients will be monitored for a minimum period of six months, in order to "determine whether the injections are causing serious adverse effects."
The cells will be monitored to ensure that they are working in a proper manner, which means that their (now deactivated) PD-1 proteins no more interrupt cell's immune response and let cancer advance.
"The hope is, without PD-1, the edited cells will attack and defeat the cancer," Nature wrote.
Naiyer Rizvi from Columbia University's Medical Center opines that could encounter a roadblock as it is a flexible method as compared to other methods like using antibodies.
"Unless it shows a large gain in efficacy, it will be hard to justify moving forward," he said.
For all the Latest Science News, Download News Nation Android and iOS Mobile Apps.
More from Science
Maternally blessed at the age of 45 years after being childless for 16 years
ISRO congratulates NASA and SpaceX for their "historic" manned mission
Four Indian cosmonauts resume training in Russia for Gaganyaan mission
17 pc decline in global carbon emissions due to COVID-19 lockdown: Study
Good News: NASA develops high-pressure ventilator to fight COVID-19